Integrated Proteomics and Metabolomics Analysis — Enzyme-Metabolite Causal Networks, Pathway Validation and Drug Target Confirmation

Proteomics and Metabolomics Integration — Why the Enzyme-Metabolite Link Is the Most Direct Causal Chain in Multi-Omics

Proteomics measures which enzymes are actually present — the catalytic machinery that executes biochemistry. Metabolomics measures the substrates and products of those enzymes — the biochemical output.

Unlike transcriptomics, where mRNA levels are buffered by translation efficiency, protein half-life, and post-translational modification, the proteome-metabolome relationship is mechanistically tight. If a rate-limiting enzyme increases in abundance, its downstream metabolite pools shift — directly, measurably, and without intermediate regulatory layers. This makes proteomics-metabolomics integration the strongest multi-omics approach for confirming causality: when both the enzyme AND its metabolic products move together, you have dual-layer evidence that the pathway is genuinely perturbed.

Our integrated analysis connects these two layers through multiple complementary approaches:

• Enzyme-substrate correlation — direct pairwise linkage of differentially abundant enzymes to their cognate metabolite pools, identifying rate-limiting enzymatic steps where protein-level changes drive metabolic flux.
• KEGG pathway co-mapping — both differentially expressed proteins and differentially accumulated metabolites overlaid onto shared biochemical pathways, identifying convergent regulation at the enzyme-metabolite level.
• Target engagement validation — proteomic evidence of target binding combined with metabolomic evidence of downstream pathway modulation provides orthogonal confirmation that a drug or genetic perturbation is hitting its intended target.

What Problem Do We Solve?

Most multi-omics studies stop at parallel lists — differentially expressed proteins here, differentially abundant metabolites there. The mechanistic insight is in the enzyme-metabolite linkage, and that is where most projects need the most support. Creative Proteomics resolves this with an analysis framework designed for causal inference:

• Enzyme-metabolite causal networks, not just correlation: We map each differentially abundant enzyme to its KEGG-annotated substrates and products, building directed enzyme→metabolite causal chains. A correlation without a known biochemical link is flagged as exploratory; a correlation with a documented enzyme-substrate relationship is treated as mechanistic evidence.
• Pathway bottleneck identification: When multiple enzymes in a pathway change but only one metabolic step shows a concentration shift, that step is the bottleneck. Our analysis identifies which enzymatic nodes actually control metabolic flux — actionable information for target prioritization and metabolic engineering.
• Dual-layer target engagement confirmation: For drug discovery programs, proteomics confirms that the compound binds its intended target (thermal shift, LiP-MS, or abundance change). Metabolomics confirms that target engagement produces the expected downstream metabolic consequence. Two orthogonal lines of evidence, one integrated analysis.

Integration Methods — From Correlation to Causal Network Inference

Different research questions require different integration strategies. The table below summarizes the key methods we apply and the questions each answers.

Not every project requires all methods. During study design, we recommend the strategy that matches your biological question and data structure. Enzyme-substrate causal mapping is recommended for all target validation and MoA studies.

Why Choose Our Integrated Proteomics and Metabolomics Analysis?

• Enzyme-Metabolite Causal Chains — Not Just Correlation
  We map differentially abundant enzymes to their KEGG-annotated substrates and products, building directed causal chains. When enzyme abundance and metabolite concentration move together within a documented biochemical relationship, you have dual-layer mechanistic evidence — not just a statistical association.
• Pathway Bottleneck Identification
  When multiple enzymes change but only one metabolic step shifts, we identify that step as the flux-controlling bottleneck. This tells you where to intervene — which enzyme to inhibit, activate, or engineer — rather than leaving you with a list of "differentially expressed" candidates.
• Target Engagement Validation with Dual-Layer Evidence
  Proteomics confirms your compound binds the target (thermal shift, abundance change, or LiP-MS). Metabolomics confirms the expected downstream metabolic shift. Together they provide orthogonal confirmation that target engagement produced functional consequence — the gold standard for MoA studies.
• End-to-End from One Provider
  DIA proteomics, LC-MS/MS metabolomics, and multi-omics integration analysis are all performed in-house on the same sample. No vendor handoffs, no format incompatibilities, no split-sample variability.

Instrumentation — DIA Proteomics and LC-MS/MS Metabolomics Platforms

Integration Software and Computational Environment

• Correlation and Causal Mapping: R (Hmisc, igraph), Python (NumPy, NetworkX); KEGG REST API for enzyme-substrate reaction annotation; WGCNA; MOFA2
• Pathway Mapping: KEGG pathview, KEGG mapper, clusterProfiler, ReactomePA, MetaboAnalyst 6.0
• Visualization: ggplot2, ComplexHeatmap, Cytoscape, Pathview (pathway overlay with protein and metabolite fold-changes)

Dual-Omics Integration Workflow — From Sample to Enzyme-Metabolite Causal Networks

Sample Requirements for Proteomics and Metabolomics — Paired Collection Guidelines

Critical Notes for Paired Proteomics-Metabolomics Studies:

• Rapid quenching is essential for metabolomics. Enzyme activity continues post-collection — metabolite pools shift within seconds. Snap-freeze or cold methanol-quench immediately. For proteomics, this is less critical (proteins are more stable), but consistent handling between paired samples is required.
• Consistent collection timing is critical. Diurnal variation affects both the proteome and metabolome. Collect all samples within a narrow time window.
• Minimum of 4–6 biological replicates per group for robust enzyme-metabolite correlation. Three replicates is the absolute minimum for differential abundance testing but limits correlation power.

Deliverables — Enzyme-Metabolite Causal Chains, Pathway Maps, and Analysis-Ready Figures

Applications of Integrated Proteomics-Metabolomics Analysis

Our dual-omics integration service supports researchers where connecting protein-level changes to metabolic consequences drives discovery:

Case Study: Proteomics-Metabolomics Integration Identifies Molecular Signatures and Drug Targets in Obesity

Integrated Proteomic and Metabolomic Profiling Identifies Distinct Molecular Signatures and Metabolic Pathways Associated with Obesity and Potential Targets for Anti-Obesity Therapies

Li, Y., Yang, H., Zhang, X., He, X., Liuli, A., Li, R., Han, X., Li, Y., and Gao, P. | Frontiers in Endocrinology, 2025, 16, 1625501

DOI: 10.3389/fendo.2025.1625501

---

Background

Obesity is a systemic metabolic disorder, but the molecular drivers within adipose tissue — the organ at the center of energy storage and endocrine dysfunction — remain incompletely characterized. Single-omics studies identify lists of candidates but cannot link protein-level changes to their metabolic consequences. Integrating proteomics and metabolomics from the same tissue samples reveals which protein abundance changes actually translate into metabolic pathway disruption.

Challenge: Characterize the proteomic and metabolomic landscape of visceral adipose tissue in obesity, identify molecular signatures that distinguish obese from healthy metabolic states, and discover regulatory proteins whose abundance changes drive downstream metabolic dysfunction — nominating them as anti-obesity drug targets.

---

Key Findings

---

What This Means for Your Dual-Omics Research

• Multi-omics integration identifies regulatory drivers that single-omics misses. OSBPL10, CUL2, and PRTN3 were identified as key regulatory candidates — not because they were the most differentially abundant proteins, but because their changes correlated with coordinated metabolite shifts in lipid metabolism and insulin signaling pathways. Our enzyme-substrate causal mapping pipeline is designed to detect exactly this kind of convergent multi-omics evidence.
• Pathway-level co-enrichment confirms biological relevance. Purine/pyrimidine metabolism and AMPK signaling were disrupted in both proteomics and metabolomics layers. Our KEGG pathway co-mapping visualizes which specific proteins and metabolites within these pathways are jointly perturbed — enabling target prioritization at the pathway level.
• Clinical follow-up data validates molecular findings. The 12-month post-surgery metabolic improvements (BMI, MASLD, lipids, liver enzymes) provide phenotypic confirmation that the identified molecular signatures reflect genuine metabolic dysfunction — not just statistical noise. This is the level of biological validation that our dual-layer evidence framework is designed to support.

---

Conclusion

This study demonstrates the power of integrated proteomics-metabolomics to move beyond candidate lists to mechanistically grounded target nomination. Our dual-omics integration service provides the same analytical framework — DIA proteomics, LC-MS/MS metabolomics, enzyme-substrate causal mapping, and KEGG pathway co-mapping — enabling you to identify which protein-level changes drive metabolic dysfunction, and which represent therapeutic opportunities.

Read the full paper: Li et al., Frontiers in Endocrinology, 2025